Heterozygous Familial Hypercholesterolaemia Clinical Trial
Official title:
A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care
Eprotirome is a liver selective thyroid hormone that can reduce several independent risk
factors for cardiovascular disease, while an euthyroid state is preserved in the
extrahepatic tissue.
The purpose of this Phase III study is to assess the long-term efficacy and safety of
Eprotirome in Patients with heterozygous Familial Hypercholesterolaemia who are on optimal
standard of care.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment